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https://doi.org/10.1016/j.immuni.2020.08.004SUMMARYMetabolic-associated fatty liver disease (MAFLD) represents a spectrum of disease states ranging from sim-
ple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic macrophages, specifically Kupffer cells (KCs),
are suggested to play important roles in the pathogenesis of MAFLD through their activation, although the
exact roles played by these cells remain unclear. Here, we demonstrated that KCs were reduced in MAFLD
being replaced by macrophages originating from the bone marrow. Recruited macrophages existed in two
subsets with distinct activation states, either closely resembling homeostatic KCs or lipid-associated mac-
rophages (LAMs) from obese adipose tissue. Hepatic LAMs expressed Osteopontin, a biomarker for patients
with NASH, linked with the development of fibrosis. Fitting with this, LAMs were found in regions of the liver
with reduced numbers of KCs, characterized by increased Desmin expression. Together, our data highlight
considerable heterogeneity within the macrophage pool and suggest a need for more specific macrophage
targeting strategies in MAFLD.INTRODUCTION
Due to the increasing prevalence of obesity and associated insu-
lin resistance, non-alcoholic fatty liver disease (NAFLD), recently
renamed metabolic associated fatty liver disease (MAFLD)
(Eslam et al., 2020), has become a global problem (Byrne and
Targher, 2015). MAFLD consists of a spectrum of disease states
ranging from simple steatosis to the more end-stage of the dis-
ease termed non-alcoholic steatohepatitis (NASH), encompass-
ing fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Not
all patients progress from the steatosis phase to NASH, and
the reasons underlying the progression remain unclear. Addi-
tionally, as there is currently no treatment for NASH, liver trans-Immunity 53, 641–657, Septem
This is an open access article undplantation is often the only option. Thus, further research is
required to understand MAFLD pathogenesis and design new
treatment strategies.
It is commonly accepted that multiple hits coming from the gut
and adipose tissue are key regulators of disease progression
(Buzzetti et al., 2016). Hepatic macrophages (macs) have been
implicated in this process, being activated to become pro-in-
flammatory by the excess lipids and damage in the fatty liver
and by signals originating from the intestine. However, it is not
clear which macs are involved. Kupffer cells (KCs) are the main
mac population in the healthy liver, where they reside with at
least part of their body in the liver sinusoids, interacting with liver
sinusoidal endothelial cells (LSECs), hepatic stellate cellsber 15, 2020 ª 2020 The Author(s). Published by Elsevier Inc. 641
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Hepatic Immune Cell Transcriptome and Surface Proteome in MAFLD
C57BL/6mice were fed either an SD orWD for 12, 24, or 36 weeks, and livers were harvested. Total live CD45+ cells were sorted (1 mouse per time point per diet),
stained with total-seq A antibodies, and loaded onto the 10X Chromium platform. After QC, 56407 cells remained.
(A) UMAP showing distinct clusters among total CD45+ live cells.
(legend continued on next page)
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has been considerable interest in the role of KCs in MAFLD,
many existing studies have relied on the use of non-specific
markers to identify ‘‘KCs,’’ together with non-specific methods
like clodronate-liposome-mediated depletion to study their func-
tions. It has recently become clear that these approaches cannot
distinguish between resident KCs (ResKCs) and other macs, re-
cruited to the liver in response to inflammation. As a result, these
poorly defined ‘‘KCs’’ have been attributed many, often contra-
dictory, roles in MAFLD, and the relative contributions of bona
fide KCs and recruited macs remain largely unknown (Remmerie
and Scott, 2018). By developing tools to identify and manipulate
KCs based on their expression of the C-type lectin, CLEC4F, we
have shown that ResKCs are replaced by monocyte-derived
KCs (moKCs) upon depletion with diphtheria toxin and that
with time, these moKCs then become resident (Scott et al.,
2016). We have previously reported a similar replacement of
the ResKC pool by moKCs in mice fed a methionine- and
choline-deficient diet (MCD), a protocol that leads to a NASH-
like disorder (Devisscher et al., 2017). However, whether this
holds true in a more clinically relevant model of MAFLD remains
to be seen.
Here, we have employed cellular indexing of transcriptomes
and epitopes by sequencing (CITE-seq) to investigate the tran-
scriptomes and surface epitopes of CD45+ cells in the livers of
mice with MAFLD, induced by feeding a Western diet (WD) for
12, 24, or 36 weeks. In combination with flow cytometry, fate
mapping, and confocal microscopy, this revealed that ResKCs
are not pro-inflammatory in MAFLD. Rather, ResKCs are gradu-
ally lost as the disease progresses, being replaced by moKCs.
Monocytes recruited to the liver also differentiated into a distinct
subset of osteopontin-expressing CLEC4F- macs with a tran-
scriptome similar to that of lipid-associated macs (LAMs) in ad-
ipose tissue (Jaitin et al., 2019) and scar-associated macs in the
fibrotic human liver (Ramachandran et al., 2019) and hence were
termed hepatic LAMs. Notably, hepatic LAMs were differentially
activated as compared with ResKCs and moKCs and had
distinct abilities to metabolize lipids. Together, our data reveal
considerable heterogeneity within the hepatic macrophage
pool in MAFLD and suggest a need for more specific mac target-
ing strategies.
RESULTS
MAFLD Induces Changes in the Transcriptome and
Surface Proteome of Hepatic Immune Cells
To assess the roles of hepatic macs in MAFLD, mice were fed a
Western diet (WD) consisting of excess fat and cholesterol and
supplemented with sucrose and fructose in the drinking water,(B) Expression of indicated proteins based on CITE-Seq antibody binding.
(C) Expression of indicated genes across the 25 clusters.
(D) Annotation of the cell types within the UMAP based on both transcriptome a
(E) Distribution of clusters from SD or WD, with SD data obtained from cells poo
(F–H) Heatmaps showing topDEGs forMonocytes (F), KCs (G), andClec4f- Macro
points. Genes in red are conserved across multiple cell types.
(I) MEM heatmap showing surface proteins whose expression was altered in at l
(J and K) CITE-Seq data were exported into FlowJo software, and (J) the KC clust
points onWD and in pooled SD-fedmice or (K) the T cell cluster was gated and CD
fed mice. See also Figure S2.a protocol generating all stages of human MAFLD and NASH
(Ganz et al., 2015). Control mice were fed a standard diet (SD).
WD-fed mice gained a significant amount of weight compared
with SD-fed mice (Figure S1A) and had an increased liver weight
and liver to body weight ratio (Figure S1B). From 12 weeks, WD-
fed mice also showed progressively elevated serum AST and
ALT, cholesterol, triglyceride and fasting insulin concentrations
as well as glucose intolerance (Figures S1C–S1F). Histological
analysis confirmed thatWD-fedmice exhibited all features of hu-
man MAFLD, with NASH developing at later time points (Cald-
well et al., 2010; Sethunath et al., 2018) (Figures S1G and
S1H), while some of these mice (1/82 at 12 weeks, 2/77 at
24 weeks, and 5/34 at 36 weeks) also developed HCC.
To investigate mac heterogeneity in MAFLD, we employed
CITE-Seq (Peterson et al., 2017; Stoeckius et al., 2017). To avoid
bias, total live CD45+ cells from the liver were isolated from a to-
tal of 6 mice (one from each of the SD- andWD-fed groups at 12,
24, or 36 weeks), stained with a panel of 112 antibodies including
isotype controls, and loaded onto the 10X Genomics Chromium
platform. After sequencing, aggregation of the samples, quality
control, removal of contaminating CD45- cells, and exclusion
of cells resembling doublets, a total of 56,407 cells remained
(6,116 cells from 12-week SD, 10,465 cells from 12-week WD,
5,357 from 24-week SD, 10,788 from 24-week WD, 11,018 cells
from 36-week SD, and 12,663 from 36-week WD). 25 clusters
could be identified by generating a UMAP from the transcrip-
tome data using 20 principal components (Figure 1A). 16
discrete cell types could be identified based on the differentially
expressed genes (DEGs) (Figure S2A, Table S1, www.
livercellatlas.org), combined with protein expression profiles
(Figures 1B, S2B, and S2C) and their expression of a set of stan-
dard cell identity genes (Figure 1C), including B cells, T cells, NK
cells, patrolling monocytes, classical monocytes, KCs (Clec4f+),
other macrophages (Clec4f-), pDCs, cDC1s, and cDC2s (Fig-
ure 1D). Three additional clusters (13, 19, and 24) were desig-
nated as neutrophils based on their protein expression of Ly6G
(Figure 1B). However, only one of these (cluster 24) expressed
mRNA for Ly6g (Figure 1C), likely reflecting the technical diffi-
culties involved in isolating good quality mRNA from neutrophils.
Examination of the distribution of cells originating from the
mice fed the different diets at each time point suggested that
many cells, including macs, B cells, and cDC1s, were altered
in MAFLD (Figure 1E). To investigate this further, we assessed
how the transcriptome of each population was affected. This
effort found multiple cell types with a set of conserved DEGs
(Figures 1F–1H and S2D; Table S1), including increased Ccl5
expression, which has previously been associated with steatosis
and fibrosis (Berres et al., 2010; Kim et al., 2018; Kirovski et al.,
2010) and decreased expression of Ccl4 and the TIS11 familynd surface proteome.
led after 12, 24, and 36 weeks.
phages (H) as assessed by comparing SD andWD samples pooled from all time
east 1 cell type during MAFLD.
er was gated and TIM4 andMerTK expression were examined at indicated time
8a and CD8b expression were examined at 36 weeks onWD and in pooled SD-
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Figure 2. Loss of TIM4+ Resident KCs and Replacement from the BM in MAFLD
(A) Gating strategy used to identify monocyte and mac populations in all figures (for full gating strategy, see Figure S3A).
(B and C) Absolute cell numbers per liver of indicated cell types frommice fed the diets for 12 (blue), 24 (green), or 36 (red) weeks, excluding mice that developed
HCC. Data are pooled from 3–7 independent experiments with n = 9–38. **p < 0.01, ***p < 0.001, ****p < 0.0001. One-way ANOVA compared with pooled SD.
(D) Schematic showing generation of protected chimeras.
(E and F)%chimerism (comparedwith bloodmonocytes) in indicated hepatic populationswas assessed in protected chimeras 18 (E) or 24 (F) weeks after feeding
the SD or WD. Data are pooled from 2 independent experiments with n = 5–9 per group.
(legend continued on next page)
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post-transcriptional gene degradation (Baou et al., 2009) (Fig-
ures 1F–1H and S2D). A number of DEGs were also cell-type
specific (Figures 1F–1H and S2D; Table S1). CITE-Seq analysis
found 5 surface proteins to be differentially expressed by one
or more cell types over time in MAFLD, including increased
expression of CD8b by T cells and reduced TIM4 on KCs (Figures
1I–1K). The increase in CD8+ T cells is in agreement with recent
findings in mice and humans (Bhattacharjee et al., 2017; Ghazar-
ian et al., 2017; Haas et al., 2019), highlighting the robustness of
our approach. Based on our previous work (Devisscher et al.,
2017; Scott et al., 2016), the decrease in TIM4 expression in
KCs suggests that ResKCs may be replaced by newly recruited
macs.Hepatic Myeloid Cells Are Heterogeneous in MAFLD
We next used flow cytometry to explore the macs present in the
liver at the different time points of MAFLD (gating strategy in Fig-
ure S3A). This found an increase in total Ly6Chi monocytes from
24 weeks on the WD compared with SD-fed mice (Figures 2A
and 2B). Although only a slight increase in the number of macs
defined as CD64+F4/80+ was observed at 24 weeks (Figures
2A and 2B), the numbers and proportions of CLEC4F+TIM4-
KCs and CLEC4F- macs increased from 24 weeks on the WD.
There was a concomitant reduction in the proportion of
CLEC4F+TIM4+ ResKCs after feeding the WD for 24 weeks,
and the number of these cells was reduced at 36 weeks (Figures
2A, 2C, and S3B). Notably, F4/80 and CD11b expression could
not discriminate between the different macs (Figure S3C). In
the fewmice with HCC, CLEC4F+TIM4+ KCs were almost absent
(Figures S3D and S3E). Increases in neutrophils, eosinophils,
cDC1s, and cDC2s from 24 weeks on the WD (Figures S3F–
S3H) were also observed, consistent with the histological evi-
dence of inflammation (Figure S1G). While the total numbers of
cDC1s and cDC2s were increased in WD-fed mice (Figure S3F),
there was a reduction in the % of cDC1s and a reciprocal in-
crease in the % of cDC2s (Figure S3G), consistent with a recent
report (Haas et al., 2019). Moreover, as recently reported (Brown
et al., 2019), hepatic cDC2s were heterogeneous in terms of
Mgl1, CCR2, and Tbet expression (Figure S3H).CLEC4F- Macs and TIM4- KCs Are Recruited from the
Bone Marrow
To test the hypothesis that CLEC4F+TIM4- KCs and CLEC4F-
macs were newly recruited from the bone marrow (BM) in
MAFLD, we generated shielded chimeras in which CD45.2
mice were irradiated with their livers protected before being re-
constituted with congenic donor BM and put on the SD or WD(G) % of Ki-67+ cells among Clec4F+ KCs in mice fed the WD for indicated time
sentative flow cytometry plots showKi67 expression byClec4F+ KCs from amous
from 3 (12 and 24 weeks) independent experiments with n = 3–24.
(H) Confocal microscopy of livers of SD or WD-fed mice (24 weeks), showing ex
Images are representative of 2 mice per diet.
(I) Absolute number of CLEC4F+TIM4+ ResKCs and CLEC4F+TIM4- moKCs in S
taneously for 4 days before being sacrificed at day 6. Data are pooled from 2 ind
Student’s t test.
(J and K) qPCR analysis for indicated genes in LSECs (J) and HSCs (K) sorted from
n = 4–6 per group. *p < 0.05, Student’s t test. All error bars indicate SEM. See a(Figure 2D). Chimerism of the hepatic monocyte and mac popu-
lations was then compared with that of blood monocytes, which
derive exclusively from the BM. 18 weeks after reconstitution,
there was no chimerism of CLEC4F+TIM4+ ResKCs in SD- or
WD-fed mice, whereas CLEC4F+TIM4- KCs and CLEC4F-
macs were chimeric, demonstrating their BM origin (Figure 2E).
As TIM4 has been described to be expressed with time (Bain
et al., 2016; Scott et al., 2016; Shaw et al., 2018), to determine
if the lack of chimerism in WD-fed ResKCs was because the
CLEC4F+TIM4- moKCs had not been in the tissue long enough
to acquire TIM4 expression, we also analyzed chimerism after
24 weeks. A small proportion of CLEC4F+TIM4+ ResKCs were
chimeric at this time, suggesting that while some moKCs may
give rise to these cells, this is likely an inefficient process (Fig-
ure 2F). Notably, local proliferation of KCs was not found to
contribute to the maintenance of their numbers in MAFLD, as
the number of Ki67+ CLEC4F+ KCs was identical in SD- and
WD-fed mice (Figures 2G and 2H). This was not due to an
intrinsic inability of the ResKCs to proliferate in the diseased liver,
as administration of CSF1-Fc to SD- or WD-fed mice (24 weeks)
induced proliferation of TIM4+ ResKCs irrespective of the diet
(Figure 2I). To determine if loss of signals originating from LSECs
or HSCs recently described to drive KC differentiation and main-
tenance (Bonnardel et al., 2019; Sakai et al., 2019) were respon-
sible for the reduced ResKC population, we examined these by
qPCR (sorted as described in Bonnardel et al., 2019) after
feeding the diets for 36 weeks. However, none of the LSEC- or
HSC-derived signals were found to be reduced (Figures 2J and
2K); thus, loss of these signals was not driving loss of ResKCs.ResKC Niche Cells Undergo Increased Proliferation
To further investigate the response of the ResKC niche cells to
MAFLD, we next performed scRNA-seq analysis of live CD45-
cells frommice fed the SD orWD for 24 and 36weeks (4 samples
in total). After sequencing, aggregation of the samples, quality
control, removal of ambient mRNA signals, alignment with the
Harmony Algorithm (Korsunsky et al., 2019), removal of contam-
inating CD45+ cells, and exclusion of cells resembling doublets,
a total of 33,241 cells remained (8,747 from 24-week SD, 11,759
from 24-weekWD, 7,247 cells from 36-week SD, and 5,488 from
36-week WD). 15 clusters could be identified by generating a
UMAP using 20 principal components (Figure 3A, www.
livercellatlas.org). 5 discrete cell types, hepatocytes, endothelial
cells, HSCs, cholangiocytes, and a small population of cells
resembling hepatic stem or progenitor cells (HpSCs), could be
identified by analysis of DEGs (Figure 3B; Table S2). Analysis
of the origins of the cells found that some clusters were predom-
inantly composed of cells originating from the WD-fed mice,points, together with pooled results from SD-fed mice (left panel) and repre-
e fed SD orWD for 24weeks (right panels). Data are from 1 (36weeks) or pooled
pression of Clec4F (green) and Ki-67 (red). White arrows indicate Ki-67+ KCs.
D- or WD-fed (24 weeks) mice injected with 1 mg/kg CSF1-Fc or PBS subcu-
ependent experiments, with n = 4–6 per group. *p < 0.05, **p < 0.01, unpaired
SD- (black) or WD-fed (red) mice (36 weeks). Data are from 1 experiment, with
lso Figure S3.
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Figure 3. Changes in Hepatic Structural Cells in MAFLD
C57BL/6mice were fed an SD orWD for 24 or 36 weeks, and livers were harvested. Live CD45- cells were then sorted (1mouse per time point per diet) and loaded
onto the 10X Chromium platform. After QC, 33,241 cells remained.
(A) UMAP showing distinct clusters among total CD45- live cells.
(B) Expression of indicated genes across the 5 cell types.
(legend continued on next page)
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that these clusters were proliferating endothelial cells and hepa-
tocytes respectively (Figure 3D). qPCR for Mki67 expression on
purified cells frommice fed the diets for 36 weeks confirmed this
increase in proliferation in LSECs and also identified increased
proliferation in HSCs and Cholangiocytes (Figure 2E). A trend to-
ward increased proliferation was also observed in the hepato-
cytes. Confocal microscopy for Ki-67 in mice fed either diet for
36 weeks further confirmed an increase in proliferation in MAFLD
with Ki-67+ cells (Figure S4A).
In addition to increased proliferation, we also investigated other
changes in the transcriptomes of the niche cells. To account for
the heterogeneity between clusters of the same cell type (primarily
due to zonation in hepatocytes and zonation and distinct endothe-
lial cell subsets in endothelial cells) (Halpern et al., 2018; 2017)
(Figures S4B–S4D), we examined DEGs between the different
clusters frommice fed the SDorWD for 24 or 36weeks. This iden-
tified a number of conserved DEGs between the clusters (Figures
3F andS4E; Table S3). Some of thesewere found after feeding the
WD for 24 and 36weeks, while somewere specific to themice fed
the WD for 36 weeks (Figures 3F and S4E). Any DEGs moving in
different directions at 24 and 36 weeks were excluded. Two
conserved downregulated genes in the niche cells (Fos & Zfp36)
were also observed in the CD45+ cells (Figures 1F–1H and S2D);
however, the relevance of this remains to be examined. Some of
the DEGs were confirmed using qPCR (Figure 3G); this included
Cd36 and Fabp4, indictive of the increased lipid load. Conversely,
we were not able to validate some of the DEGs shown in the
scRNA-seq analysis, such as Hspa5 (Figure 3G). Moreover,
confocal microscopy for HSPA5 also did not reveal any differ-
ences in protein expression (Figure S4G); however, as this primar-
ily stained the hepatocytes, this analysis demonstrated the
increased size of hepatocytes in WD- compared with SD-fed
mice (Figure S4G). These results highlight that while the expres-
sion of signals important for ResKC development and mainte-
nance are not lost in MAFLD, the niche cells have an altered tran-
scriptome and also undergo increased proliferation in MAFLD.
Additionally, hepatocytes increase in size which could alter the
distribution of signals to ResKCs. These alterations to the niche
could therefore play a role in the loss of ResKCs in MAFLD.Recruited Macrophages Colonize the ResKC Niche
Having identified changes in the ResKC niche inMAFLD, we next
set out to explore whether resident and recruitedmacs occupied
the same or distinct niches in MAFLD. We therefore localized
CLEC4F+TIM4+ ResKCs, CLEC4F+TIM4- moKCs, and CLEC4F-
macs using confocal microscopy after feeding the SD or WD
for 12, 24, and 36 weeks. This revealed that all MAFLD macs, ir-
respective of CLEC4F and TIM4 expression, were located in the
zones between the portal and central veins, with at least a part of(C) Distribution of clusters from SD- or WD-fed mice at 24 weeks (green) or 36 w
(D) Expression of Mki67 across the different clusters.
(E) Expression of Mki67 as determined by qPCR on indicated cells sorted from
experiment, with n = 4–6 per group. *p < 0.05, **p < 0.01, Student’s t test. Error
(F) Heatmaps showing top 40 DEGs in the indicated cells types between SD- and
altered at the 36-week time point.
(G) qPCR analysis for indicated genes in indicated cell populations. Data are from
indicate ±SEM. See also Figure S4.their body in contact with LSECs (CD31+) and hepatic stellate
cells (Desmin+) (Figures 4A–4C). This location was identical to
that observed for ResKCs in healthy liver (Bonnardel et al.,
2019). Notably, there were also some CLEC4F- macs found in
close proximity to the large vessels (central & portal veins), but
these were also found in the SD-fedmice (Figure 4B). Automated
identification of the macs based on expression of F4/80 followed
by classification into TIM4+ KCs, TIM4- KCs, or CLEC4F- macs
identified similar proportions of the different subsets as retrieved
by flow cytometry (Figures 4B, 4C, and S3B). However, this iden-
tified regions where CLEC4F- macs were the main mac subset
present (Figures 4A and 4B). These zones were characterized
by increased Desmin expression (Figures 3D and 3E), a charac-
teristic of fibrotic stellate cells and myofibroblasts (Ballardini
et al., 1988). Thus, these findings suggest that recruited macs
populate the ResKC niche in MAFLD, with CLEC4F- macs being
predominantly found in fibrotic zones.Recruited Macs Exist in Distinct Subsets
We next investigated the similarities and differences between
CLEC4F- macs and KCs. To this end, we isolated cells of the
monocyte and mac lineages from the CITE-seq data (18,241
cells) and re-clustered them (Figures S5A and 4F, www.
livercellatlas.org). The sub-clusters revealed by this additional
analysis varied between diets and time points (Figures 4G and
S5B). Analysis of the DEGs and surface proteins expressed per
cluster allowed them to be identified more precisely (Figures
4H, 4I and S5C–S5E). Clusters 0, 1, 3, 5, 14, and 17 were mono-
cyte-like cells (Figures 4F, S5D, and S5E; Table S3), and of these,
cluster 3 was the main population in the SD-fed mice, whereas
cluster 17 was a minor population, present in all conditions but
increased in WD-fed mice (Figures 4G and S5B). Cells in cluster
17 were enriched for IFN-induced genes, including Ifit1, Ifit3, and
Isg15 (Figure S5D; Table S3), similar to a subset of monocytes
recently reported (Ydens et al., 2020). Cluster 11 was identified
as patrolling Ly6Clo monocytes, while clusters 4, 7, 10, and 12
had features of monocytes and macs, suggesting that they
were transitioning monocytes differentiating into macs (Figures
4F, 4I, S5D, and S5E; Table S3). Clusters 6, 8, 9, 15, 22, and
23 were identified as ResKCs on the basis of their expression
of Clec4f and ResKC genes (Beattie et al., 2016; Scott et al.,
2016), including Timd4, C2, Xlr, Marco & Cd163 (Figures 4H,
S5D, and S5E; Table S3). Of these, cluster 6, enriched for genes
associated with inflammation, was restricted to the mouse fed
the SD for 36 weeks (Figures 4G, S5B, and S5F; Table S4). How-
ever, no significant differences in the expression of these genes
were observed by qPCR (Figure S5G).
Clusters 2, 13, 16, 18, 19, 20, and 21 were also identified as
macs. Of these, clusters 19 and 21 were proliferating cells con-
taining Clec4f+ KCs and Clec4f- macs (Figures 4H, S5D, andeeks (red).
livers of SD- or WD-fed mice (12, 24, and 36 weeks). Data are from a single
bars indicate ±SEM.
WD-fed mice (24 and 36 weeks). Genes in green represent DEGs specifically
a single experiment, with n = 4–5 per group. *p < 0.05, **p < 0.01. Error bars
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Figure 4. Localization and Heterogeneity of Macrophages in MAFLD
(A) Confocal microscopy showing cells expressing CLEC4F (red), F4/80 (green), TIM4 (blue), and CD31 (gray) in the livers of SD- or WD-fed mice at the indicated
time points. Smaller images show results for individual channels; the larger image is merged from all channels. Scale bar, 50 mm. Images are representative of 5–6
mice per time point and are extracted from 4 3 4 tiled images. White arrows point to CLEC4F+TIM4- moKCs. Dashed line highlights the zones enriched for
CLEC4F- macs.
(legend continued on next page)
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Clec4f and many other KC signature genes, but lacking expres-
sion of ResKC genes such as Timd4 (Figures 4H, S5D, and
S5E). Based on a list of capsule mac signature genes (Table S4)
generated by comparing the gene expression profile of liver
capsule macs (Sierro et al., 2017) with those of ResKCs and Ly6-
Chi monocytes (Scott et al., 2016) andmapping the signature onto
our data using the signature finder algorithm (Pont et al., 2019),
cluster 20 was identified as liver capsule macs (Figure S5C). Clus-
ters 2 and 16, which were specific to WD-fed mice, could not yet
be further identified andwere calledMac1 andMac2, respectively
(Figure 4F). Cluster 18 identified a group of cells that shared
expression ofMmp12 (Figures S5D and S5E). However, mapping
individual cells in this cluster onto the other clusters using the
FindTransferAnchors function of the Seurat R package showed
that this was a heterogeneous population of ResKCs, moKCs,
Mac1s, and Mac2s; thus, for further analysis, they were included
with the cells of the same identity.
To determine which clusters represented the macs identified in
our flow cytometry analysis, we purified the 3 subsets based on
CLEC4F and TIM4 from SD- and WD-fed mice (12 and 24 weeks)
and performed bulk RNA-seq (Figure S6A). PCA analysis and
comparison of the 3 populations in a triwise plot revealed that
the majority of DEGs between the 3 populations were either spe-
cific to the CLEC4F- macs (Spp1, Chil3, Ccr2, and Gpr183) or
shared between the moKCs and ResKCs with the exception of
residency genes (Beattie et al., 2016; Scott et al., 2016) specific
to the ResKCs, including Timd4, Cd163, C6, Xlr, and Marco (Fig-
ure S6A). To define the signature of each population, we
compared the cells to one another and took the genes with a
Log fold change (FC) >2. This process was refined for the
CLEC4F- macs by an additional comparison of their DEGs with
BM monocytes. Similarly, an additional comparison was carried
out between moKCs and ResKCs, to ensure selection of DEGs
that were unique to the moKC population. Using the signature
finder algorithm (Pont et al., 2019) to map the resulting signatures
(Table S5) onto the scRNA-seq data (Figure S6B), we confirmed
the annotations of the populations in the scRNA-seq data.
Notably, while the CLEC4F- macs mapped primarily onto the
Mac2s, they also showed some similarities to the Mac1s (Fig-
ure S6B), indicating that the CLEC4F- cells are heterogeneous.
Hepatic Lipid-Associated Macs Differentiate in MAFLD
To investigate the heterogeneity of the CLEC4F- macs, we used
triwise plots to define the DEGs that separated the as yet un-(B) Tile scans (4x4) of livers fromSD- andWD-fedmice (36weeks) showing annota
lines) identify the areas from the WD-fed mouse used in (A). Shaded gray boxes
fication analysis in (C) and (E). Images are representative of 6 mice.
(C) Quantification of indicated populations shown in (B) as a % of total F4/80+ ma
bars indicate ±SEM.
(D) Tile scan of liver from a WD-fed mouse (36 weeks; same mouse as from A and
classified as Desminlo, excluding the larger vessels, for quantification in (E).
(E) Quantification of indicated populations in Desminhi and Desminlo zones (fromD
area. Quantification data in (C) and (E) are pooled from 2 independent experimen
(F–I) Monocyte- andmac-containing clusters (based on expression ofMafb, Ly6c2
re-clustered.
(F) UMAP showing annotated monocyte and macrophage clusters.
(G) Distribution of cells on SD or WD at indicated time points, with SD data com
(H and I) Expression of indicated genes by the different clusters (SD + WD pooleidentified Mac1s and Mac2s from the other recruited popula-
tion, the moKCs (Figure S6C). Comparison of these DEGs
with ResKCs confirmed the similarity between moKCs and
ResKCs, while the 2 unidentified mac clusters were distinct
(Figure 5A; Table S4). The Mac1s were enriched for genes
such as Cx3cr1, Itgax, H2-M2, and Olfml3, while the Mac2s
were enriched for Spp1, F10, Chil3, Fabp5, andGpnmb expres-
sion (Figures 5A and S6C–S6E). Notably, the gene expression
profile of Mac1s somewhat resembles moKCs (Figure 5A) and
macs en route to becoming moKCs (Bonnardel et al., 2019).
While this manuscript was under review, Clec1b (encoding
CLEC2) was proposed to be a good marker of moKCs that ap-
peared to be expressed earlier than CLEC4F (Tran et al., 2020).
To confirm this, we examined expression of CLEC4F and
CLEC2 in Clec4f-DTR mice (Scott et al., 2016) 3 and 6 days
post-ResKC depletion during the generation of moKCs (Scott
et al., 2016). This analysis confirmed CLEC2 to be an early
marker of macs becoming moKCs, and hence, we termed the
CLEC2+CLEC4F- macs ‘‘pre-moKCs’’ (Figure S6F). As the
Mac1s seemed to resemble macs en route to becoming
moKCs, we checked if these would be pre-moKCs. Fitting
with the scRNA-seq data, the CLEC4F- macs could be split
into 2 populations based on CLEC2 expression (Figures S6D
and S6G). Thus, Mac1s are pre-moKCs. To define Mac2s, we
next performed KEGG pathway analysis (Table S4). This sug-
gested the Mac2s to be relevant in diseases, including MAFLD
(Figure 5B). While Cd9 and Trem2 expression was increased
across mac subsets in MAFLD (Table S6), the overall signature
of the Mac2s closely resembled those of Cd9- and Trem2-ex-
pressing lipid-associated macrophages (LAMs) described
recently in obese adipose tissue (AT; Figure S6H) (Hill et al.,
2018; Jaitin et al., 2019), suggesting that this cluster may be
their hepatic counterpart. Indeed, when we calculated the
signature of the AT LAMs compared with other AT macs (Jaitin
et al., 2019) (Table S7), the signature finder algorithm (Pont
et al., 2019) mapped the LAM signature onto the Mac2s (Fig-
ure 5C). Thus, we called these cells hepatic LAMs. Comparison
of the DEGs between hepatic and AT LAMs identified 67 DEGs
with a Log FC >1.5, indicating tissue-specific influences on the
differentiation of these cells (Figure S6I; Table S7). The hepatic
LAMs also showed some overlap with the scar-associated
macs that have recently been described in fibrotic human livers
(Ramachandran et al., 2019) and whose signature is also en-
riched for expression of TREM2 and CD9 (Figure S6J). Exami-
nation of the CITE-seq data did not reveal any specifiction of identifiedmacs per subset in indicated colors. Indicated regions (dashed
identify large vessels (portal or central veins) that were excluded from quanti-
cs. **p < 0.01, ****p < 0.0001, Student’s t test compared with SD control. Error
B) with identified Desminhi regions demarcated in blue. The rest of the tissue is
) as a%of eachmac subset. *p < 0.05, Student’s t test comparedwith Desminlo
ts with n = 6. Error bars indicate ±SEM.
,Ccr2, Fcgr1,Adgre1) were isolated from the CITE-Seq data (18,241 cells) and
ing from cells pooled after 12, 24, and 36 weeks.
d). See also Figure S5.
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Figure 5. Hepatic LAMs in MAFLD Are Identified by Spp1 Expression
(A) Heatmap showing DEGs between Mac2, Mac1, and moKC populations from mice fed the WD for 24 and 36 weeks pooled and their expression by indicated
populations.
(B) KEGG pathway analysis on DEGs for each indicated subset (see Tables S1 and S3).
(legend continued on next page)
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OPEN ACCESSArticleantibodies for phenotypic analysis of the hepatic LAMs, while
flow cytometry analysis of potential surface markers showed
reactivity that was either non-selective (e.g. CD9) (Figures 5D
and 5E) or gave no signal above controls (GPNMB, CD63;
data not shown). Thus, we next examined other suitable
markers of the LAM population and identified Spp1 to be spe-
cifically enriched in LAMs (Figure 4I). As Spp1 encodes the che-
mokine osteopontin, implicated in fibrosis and NASH (Arriazu
et al., 2017; Glass et al., 2018), we tested whether it could be
used as a marker of hepatic LAMs. Using the PrimeFlow assay
to measure mRNA transcripts by flow cytometry, we detected
Spp1 primarily in CLEC4F- macs, identifying the hepatic
LAMs (Figures 5D and 5E). While the SPP1 antibody proved un-
suitable for flow cytometry, we were able to confirm the
presence of SPP1-expressing macs in MAFLD by immunofluo-
rescence, using EPCAM to exclude SPP1-expressing cholan-
giocytes (Figures 5F and 3B).Hepatic LAMs and KCs Have Distinct Abilities to
Metabolize Lipid
We next sought to investigate how the different macs
compared functionally. We first examined expression of a list
of generic prototypical immune activation-associated genes
in hepatic LAMs, pre-moKCs, moKCs, and ResKCs pooled
from mice fed the WD (24 and 36 weeks). Overall, the different
KCs expressed these genes similarly, while hepatic LAMs ex-
pressed lower Il18, Fpr2, Tlr4, Cd38, Tgm2, Mrc1, and Abca1
and higher Spp1, Ccl3, Itgax, Socs3, Chil3, and Plin2 (Figures
6A and S7A). We next examined expression of lipid metabolism
genes, as this is proposed to be a main function of ResKCs.
This revealed a similar pattern in which moKCs were similar
to ResKCs, with the exception of Apoc1 (lower) and Pparg
(higher), whereas LAMs showed lower or equal expression of
most of these genes compared with the KC populations, with
the exception of Lpl & Pparg (Figures 6B and S7B). Pre-moKCs
had an intermediate phenotype between the KCs and the LAMs
(Figure 6B). Consistent with these findings, CLEC4F-macs con-
tained fewer neutral lipids than their ResKC or moKC counter-
parts (Figure 6C), as measured by BODIPY or LIPIDTOX stain-
ing. Despite containing more neutral lipid than CLEC4F- macs,
moKCs also contained less lipid than the ResKCs (Figure 6C).
To examine this further, we performed lipidomic analysis. Due
to a number of factors including cell numbers required, the
lack of a Spp1 antibody, the lack of knowledge of CLEC2
expression at the time of analysis, and the overall similarity be-
tween ResKCs and moKCs, we compared total CLEC4F+ KCs
with CLEC4F- macs. This showed that although KCs and
CLEC4F- macs shared some lipid species, others were found
only in KCs and not in CLEC4F- macs (Figure 6D), further sug-(C) The adipose tissue LAM signature (Jaitin et al., 2019) was mapped onto the li
algorithm (Pont et al., 2019).
(D and E) Expression of Spp1 by CLEC4F- macrophages (D) and moKCs and Re
representative plots), and right, proportions of indicated populations (T4 = TIM4)
0.001, ****p < 0.0001. One-way ANOVA. Error bars indicate ±SEM.
(F) Confocal microscopy (2x2 Tiles) showing expression of F4/80 (blue), SPP1 (gr
(gray) in livers of SD- and WD-fed mice (36 weeks). Scale bar, 100 mm. White a
colocalization of SPP1 and F4/80 signal (36 weeks WD). Scale bar, 10 mm. Ima
Figure S6.gesting that these cells have distinct abilities to metabolize
lipids. Thus, hepatic LAMs and moKCs represent distinct fates
for monocytes recruited to the liver in MAFLD in terms of their
transcriptome, localization, and function.ResKCs Are Not Pro-inflammatory in MAFLD
Finally, we examined how ResKCs responded in MAFLD. The
gradual loss of ResKCs duringMAFLD indicates that these cells
are affected by the lipemic environment, and it is generally
believed that immune activation of KCs occurs inMAFLD (Kren-
kel and Tacke, 2017). However, the exact effects of MAFLD on
KCs are contentious (Morgantini et al., 2019; Xiong et al., 2019).
Consistent with a recent report (Morgantini et al., 2019), we did
not observe immune activation of KCs at any stage of MAFLD in
either the scRNA-seq or bulk RNA-seq analysis, as evidenced
by expression of genes associated with immune cell activation.
Although we observed a slight decrease in Tnfa, Il1b, and Il10
expression in ResKCs from WD-fed mice (Figures 7A and
S7C), no differences were found in pro-inflammatory cytokine
production (Figure 7B), thus demonstrating that ResKCs are
not pro-inflammatory in MAFLD. Furthermore, although
changes could be seen in the ResKC transcriptome when
examining all the DEGs between SD- and WD-fed mice at the
different time points, the scale of these changes was modest
compared with the differences between KCs and CLEC4F-
macs (Table S6). Using a log FC >1.5 as a cut-off, analysis of
the scRNA-seq data revealed 2 DEGs in ResKCs at 12 weeks,
0 DEGs at 24 weeks, and 13 DEGs at 36 weeks (Figure 7C).
Analysis of the more in-depth bulk RNA-seq data showed 1
DEG in WD ResKCs at 12 weeks and 100 DEGs at 24 weeks,
compared with 781 DEGs between WD ResKCs and CLEC4F-
macs at 24 weeks (Figure S7D; Table S6). KEGG pathway anal-
ysis suggested that many of the upregulated genes in WD
ResKCs were associated with cell adhesion and cytokine-re-
ceptor interactions (data not shown). There was also some
increased expression of genes associated with metabolically
activated macs (MMe) in ResKCs from mice with MAFLD (Fig-
ures 7A and S7C); however, this did not correlate with a differ-
ence in the ResKC metabolome between SD and WD
(12 weeks), although the ResKC profile was distinct from
in vitro M0, M1, and M2 macrophages (Figures 7D and S7F).
Moreover, LIPIDTOX and BODIPY staining showed that the
neutral lipid content of ResKCs did not increase in WD-fed
mice at 12, 24, or 36 weeks (Figures 7E–7G); rather, there
was a slight decrease after 36 weeks (Figures 7E and 7F). Anal-
ysis of the ResKC lipid metabolism profile at the different time
points on the diet identified a trend toward slightly increased
expression of these genes in WD-fed mice (Figures 7H and
S7E), possibly compensating for the increased lipid load.ver mac UMAP to identify cells with a similar profile using the Signature Finder
sKCs (E) at 24 and 36 weeks on WD as measured by Prime Flow (left panels,
. Data are pooled from 2 experiments with 6 mice per group. *p < 0.05, ***p <
een), EPCAM (yellow), CD31 (red), Desmin (cyan), and tissue autofluorescence
rrows identify SPP1+ macrophages. Inset shows zoomed in images showing
ges are representative of 6 mice from 2 independent experiments. See also
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Figure 6. Characterization of Recruited Macrophages in MAFLD
(A) Heatmap showing expression of immune activation-associated genes in ResKCs, moKCs, pre-moKCs and hepatic LAMs from WD-fed mice (24 and
36 weeks, pooled).
(B) Heatmap showing expression of genes associated with lipid metabolism previously reported to be enriched in ResKCs (Scott et al., 2016) in ResKCs, moKCs,
pre-moKCs, and hepatic LAMs from WD-fed mice (24 and 36 weeks, pooled).
(C) Neutral lipid content of ResKCs (T4+), moKCs (T4-), and CLEC4F- macs (C4-) after 12, 24, and 36 weeks on WD. Results shown are geometric mean for
Lipidtox and BODIPY staining normalized to Ly6Chi monocytes from the same liver. *p < 005, ***p < 0.001, ****p < 0.0001. One-way ANOVA compared with
ResKCs at each time point. Error bars indicate SEM.
(D) Lipidomics analysis of sorted CLEC4F+ KCs and CLEC4F- macs from WD-fed mice (24 weeks). Left: PCA plot showing results for different macs. Right:
indicated lipid species in CLEC4F+ KCs (C4+) or CLEC4F- macs (C4-). **p < 0.01 Student’s t test. Error bars indicate ±SEM. See also Figure S6.
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OPEN ACCESS ArticleFocused ion beammilling combined with scanning electron mi-
croscopy (FIB-SEM) and lipidomics analysis also did not iden-
tify any overt differences in either lipid droplet volume or in the
lipid species present in CLEC4F+ KCs isolated from mice fed
the SD or WD (Figure S7G; data not shown). Taken together,
this suggests that while ResKCs react in MAFLD, they are not
pro-inflammatory, nor do they harbor an increased or altered
lipid load. Thus, the biggest difference in MAFLD macs stems652 Immunity 53, 641–657, September 15, 2020from the recruitment of LAMs which are distinct from ResKCs,
moKCs, and pre-moKCs, highlighting the need to differentiate
between these mac subsets.
DISCUSSION
MAFLD represents a spectrum of disease states ranging from
simple steatosis to NASH, which can lead to cirrhosis and
Figure 7. Features of ResKCs in MAFLD
(A) Heatmap showing expression of immune activation-associated genes by ResKCs after 12, 24, and 36 weeks on the WD, compared with SD (gray) from the
same time point.
(B) Pro-inflammatory cytokine expression by ResKCs at indicated time points in either SD- or WD-fed mice as measured by intracellular cytokine staining. Data
are pooled from 2 experiments, with n = 7–19 mice per group. Error bars indicate ±SEM.
(C) Volcano plots showing DEGs between ResKCs (SD or WD) for indicated time points.
(D) PCA plot showing metabolomic analysis (non-polar and polar metabolites) of ResKCs after 12 weeks on SD orWD compared with in vitro polarized M0, M1 or
M2 BM-derived macrophages. Data are from a single experiment, with n = 3–5 per group.
(legend continued on next page)
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OPEN ACCESS ArticleHCC. However, not all patients progress from MAFLD to NASH,
and while the reasons why some do and some don’t remain
largely unclear, hepatic macs have been proposed to play a
role in this. Recently, it has become clear that hepatic macs,
especially in disease settings, do not represent a homogeneous
population of ResKCs but rather can exist in multiple subsets
and/or activation states (Remmerie et al., 2020; Xiong et al.,
2019). To begin to assess the roles played by the distinct mac
populations in MAFLD, we set out to characterize mac heteroge-
neity and localize the subsets within the liver. We identified four
subsets of hepaticmacs inMAFLD, including ResKCs and 3 sub-
sets of recruited macs, moKCs, pre-moKCs, and the distinct he-
patic LAMs. Notably, all populations were found within the KC
niche in contact with hepatic stellate cells (HSCs) and liver sinu-
soidal endothelial cells (LSECs) (Bonnardel et al., 2019). Howev-
er, LAMs were predominantly found in regions characterized by
increased Desmin expression, suggestive of fibrosis. During re-
viewing, two additional papers were published investigating
macs in MAFLD (Seidman et al., 2020; Tran et al., 2020). It is
currently unclear exactly how the populations identified here
correlate to those described by Seidman et al. (2020). Compar-
ison of the datasets would suggest that the hepatic LAMs would
most likely be present in the KN-RM gate; however, with the
expression pattern of F4/80, TIM4, and CD11b, some LAMs
may also be in the Ly6Clo-RM gate (Seidman et al., 2020). How-
ever, as distinct diets were used, this may also affect the popu-
lations present. With this in mind, it will also be important to
examine whether LAMs are found within CLEC2- macs recruited
in the MCD-model (Tran et al., 2020). Additionally, Xiong et al.
(2019) have also described a population of macs termed
NASH-associated macs (NAMs). In contrast to our study, the
NAMs were identified as KCs. However, only a subset of these
cells expressed KC identity genes like Cd5l or Clec4f (Remmerie
et al., 2020; Xiong et al., 2019), suggesting that these may also
include LAMs.
How important is the distinction between the recruited mac
subsets? While others have suggested minimal differences be-
tween TIM4- macs and ResKCs in NASH (Seidman et al.,
2020), by dividing the population into moKCs and LAMs, we
identified that moKCs largely resembled ResKCs, while LAMs
had more than 700 DEGs compared with ResKCs, including dif-
ferences in lipid metabolism and immune activation. Moreover,
as the hepatic LAMs best resemble scar-associated macro-
phages described in fibrotic human livers (Ramachandran
et al., 2019), this distinction is also clinically relevant. Moreover,
hepatic LAMs expressed Spp1 encoding the chemokine Osteo-
pontin. Osteopontin has recently been described as a good
biomarker of NASH in patient serum (Glass et al., 2018). Thus,
as hepatic LAMs were only identified in the later stages of dis-
ease correlating with worsening disease and fibrosis, it is
tempting to speculate that this increase in osteopontin observed
in patients could be attributed to the hepatic LAMs. In addition,(E and F) Neutral lipid content of ResKCs after 12, 24, and 36weeks onWD compa
staining normalized to Ly6Chi monocytes from the same livers. *p < 0.05. One-w
(G) Sorted ResKCs from SD- or WD-fed mice (12 weeks) were allowed to adhe
microscopy.
(H) Heatmap showing expression of genes associated with lipid metabolism pr
Figure S7.
654 Immunity 53, 641–657, September 15, 2020osteopontin has been implicated in driving collagen I production
from HSCs (Seth et al., 2014) and thus is thought to contribute to
fibrosis (Arriazu et al., 2017). This could suggest that hepatic
LAMs drive the progression to NASH. Indeed, recent studies
blocking osteopontin in mice models of NASH have suggested
a protective effect (Coombes et al., 2016; Honda et al., 2020;
Kiefer et al., 2010). Unfortunately, to date, we do not have the
tools to target this population specifically to address these ques-
tions, but generating these is an important aim for the future.
Turning our attention to the ResKCs, we found that, contrary to
the current line of thinking (Reid et al., 2016; Tosello-Trampont
et al., 2012; Krenkel and Tacke, 2017), ResKCs are not pro-in-
flammatory in MAFLD. Thus, this questions the proposed role
of KCs as drivers of NASH, through their role as inflammatory
mediators (Krenkel and Tacke, 2017). While not pro-inflamma-
tory, ResKCs had an altered transcriptome in MAFLD; however,
the scale of these changes was modest compared with differ-
ences between ResKCs and LAMs. Moreover, minor, if any,
changeswere observed in themetabolomics and lipidomics pro-
files of KCs. One possibility is that the modest response
observed here is because we can only profile the remaining
ResKCs. Perhaps if we were to catch the ResKCs just prior to
their loss, increased differences would be observed. Themodest
response of ResKCs is in contrast to a recent report, where over
800 DEGs genes have been identified between NASH and
healthy ResKCs. For example, we did not observe the altered
expression of C6 or Cd163 (Seidman et al., 2020). The reasons
for these differences remain unclear but could be related to the
timing or diet used. As many KC residence and identity genes
were downregulated in NASH TIM4+ KCs in the study from Seid-
man et al. (2020), one possibility is that the proportion of moKCs
acquiring TIM4 expressionmay be different between themodels,
leading to a more immature KC profile in NASH in the study from
the Glass lab. Indeed, many of the DEGs reported between
NASH and healthy KCs, including C4b, Timd4, Marco, and
Hmox1, were dysregulated between our moKCs and ResKCs.
However, overall, the differences between moKCs and ResKCs
in our model were also relatively modest (72 DEGs, LogFC > 1.5).
Despite these differences, our observation that ResKCs were
gradually lost from the tissue in MAFLD is consistent with the
other recent studies (Seidman et al., 2020; Tran et al., 2020).
Regarding why ResKCs fail to self-maintain in MAFLD, one hy-
pothesis is that they are no longer correctly adapted to the niche.
While our data did not identify any major changes in the niche
signals important for KC development and maintenance (Bon-
nardel et al., 2019; Sakai et al., 2019), we observed an increase
in niche cell proliferation, suggesting an increased need to main-
tain cell numbers in MAFLD. Moreover, we also identified differ-
ences in the transcriptomes of these cells. However, further work
is required to better understand the precise signals at play. With
the knowledge that ResKCs have been suggested to be protec-
tive in NASH (Tran et al., 2020), our data suggesting a lack ofred with SD. Results shown are geometric mean for (E) Lipidtox and (F) BODIPY
ay ANOVA compared with SD at each time point. Error bars indicate ±SEM.
re to a coverslip and stained for Lipidtox and DAPI and imaged by confocal
ofile in ResKCs from the mice fed either the SD or WD (36 weeks). See also
ll
OPEN ACCESSArticleResKCs in HCC and the finding that osteopontin expression cor-
relates with worse disease (Glass et al., 2018), perhaps if we can
understand the signals driving ResKC loss and LAM generation
inMAFLD, this could open the door to therapeutic options for pa-
tients to prevent and/or reverse progression to NASH and HCC.
Together, our data highlight the heterogeneity within the
macrophage pool in MAFLD and highlight the need for examina-
tion of this heterogeneity when considering therapeutic options.
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(CR2/CR1) Antibody (clone 7E9)
BioLegend 123427; RRID: AB_2750540
TotalSeq-A0108 anti-mouse CD23
Antibody (clone B3B4)
BioLegend 101635; RRID: AB_2750358
TotalSeq-A0109 anti-mouse CD16/32
Antibody (clone 93)
BioLegend 101343; RRID: AB_2750532
TotalSeq-A0110 anti-mouse CD43
Antibody (clone S11)
BioLegend 143211; RRID: AB_2750541
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TotalSeq-A0111 anti-mouse CD5
Antibody (clone 53-7.3)
BioLegend 100637; RRID: AB_2749985
TotalSeq-A0112 anti-mouse CD62L
Antibody (clone MEL-14)
BioLegend 104451; RRID: AB_2750364
TotalSeq-A0113 anti-mouse CD93
(AA4.1, early B lineage) Antibody
(clone AA4.1)
BioLegend 136513; RRID: AB_2750375
TotalSeq-A0114 anti-mouse F4/80
Antibody (clone BM8)
BioLegend 123153; RRID: AB_2749986
TotalSeq-A0115 anti-mouse FcεRIa
Antibody (clone MAR-1)
BioLegend 134333; RRID: AB_2749987
TotalSeq-A0117 anti-mouse I-A/I-E
Antibody (clone M5/114.15.2)
BioLegend 107653; RRID: AB_2750505
TotalSeq-A0118 anti-mouse NK-1.1
Antibody (clone PK136)
BioLegend 108755; RRID: AB_2750536
TotalSeq-A0119 anti-mouse Siglec H
Antibody (clone 551)
BioLegend 129615; RRID: AB_2750537
TotalSeq-A0130 anti-mouse Ly-6A/E
(Sca-1) Antibody (clone D7)
BioLegend 108147; RRID: AB_2750535
TotalSeq-A0171 anti-human/mouse/rat
CD278 (ICOS) Antibody (clone C398.4A)
BioLegend 313555; RRID: AB_2800824
TotalSeq-A0173 anti-mouse CD206
(MMR) Antibody (clone C068C2)
BioLegend 141735
TotalSeq-A0184 anti-mouse CD335
(NKp46) Antibody (clone 29A1.4)
BioLegend 137633; RRID: AB_2734199
TotalSeq-A0190 anti-mouse CD274
(B7-H1, PD-L1) Antibody (clone MIH6)
BioLegend 153604; RRID: AB_2783125
TotalSeq-A0191 anti-mouse/rat/human
CD27 Antibody (clone LG.3A10)
BioLegend 124235; RRID: AB_2750344
TotalSeq-A0192 anti-mouse CD20
Antibody (clone SA275A11)
BioLegend 150423; RRID: AB_2734214
TotalSeq-A0193 anti-mouse CD357
(GITR) Antibody (clone DTA-1)
BioLegend 126319; RRID: AB_2734195
TotalSeq-A0194 anti-mouse CD137
Antibody (clone 17B5)
BioLegend 106111; RRID: AB_2783048
TotalSeq-A0195 anti-mouse CD134
(OX-40) Antibody (clone OX-86)
BioLegend 119426; RRID: AB_2750376
TotalSeq-A0197 anti-mouse CD69
Antibody (clone H1.2F3)
BioLegend 104546; RRID: AB_2750539
TotalSeq-A0198 anti-mouse CD127
(IL-7Ra) Antibody (clone A7R34)
BioLegend 135045; RRID: AB_2750009
TotalSeq-A0200 anti-mouse CD86
Antibody (clone GL-1)
BioLegend 105047; RRID: AB_2750348
TotalSeq-A0201 anti-mouse CD103
Antibody (clone 2E7)
BioLegend 121437; RRID: AB_2750349
TotalSeq-A0202 anti-mouse CD64
(FcgRI) Antibody (clone X54-5/7.1)
BioLegend 139325; RRID: AB_2750367
TotalSeq-A0203 anti-mouse CD150
(SLAM) Antibody (clone TC15-12F12.2)






BioLegend 101841; RRID: AB_2750380
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TotalSeq-A0214 anti-human/mouse
integrin b7 Antibody (clone FIB504)
BioLegend 321227; RRID: AB_2750504
TotalSeq-A0225 anti-mouse CD196
(CCR6) Antibody (clone 29-2L17)
BioLegend 129825; RRID: AB_2783083
TotalSeq-A0226 anti-mouse CD106
Antibody (clone 429 (MVCAM.A))
BioLegend 105725; RRID: AB_2783044
TotalSeq-A0227 anti-mouse CD122
(IL-2Rb) Antibody (clone 5H4)
BioLegend 105909
TotalSeq-A0228 anti-mouse CD183
(CXCR3) Antibody (clone CXCR3-173)
BioLegend 126543
TotalSeq-A0229 anti-mouse CD62P
(P-selectin) Antibody (clone RMP-1)
BioLegend N/A
TotalSeq-A0230 anti-mouse CD8b (Ly-3)
Antibody (clone YTS156.7.7)
BioLegend 126623; RRID: AB_2800615
TotalSeq-A0232 anti-mouse MAdCAM-1
Antibody (clone MECA-367)
BioLegend 120713; RRID: AB_2783058
TotalSeq-A0236 Rat IgG1, k Isotype Ctrl
Antibody (clone RTK2071)
BioLegend 400459
TotalSeq-A0237 Rat IgG1, l Isotype Ctrl
Antibody (clone G0114F7)
BioLegend 401919
TotalSeq-A0238 Rat IgG2a, k Isotype Ctrl
Antibody (clone RTK2758)
BioLegend 400571
TotalSeq-A0240 Purified Rat IgG2c, k
Isotype Ctrl Antibody (clone RTK4174)
BioLegend 400739
TotalSeq-A0241 Armenian Hamster IgG
Isotype Ctrl Antibody (clone HTK888)
BioLegend 400973
TotalSeq-A0250 anti-mouse/human
KLRG1 (MAFA) Antibody (clone
2F1/KLRG1)
BioLegend 138431; RRID: AB_2800648
TotalSeq-A0376 anti-mouse CD195
(CCR5) Antibody (clone HM-CCR5)
BioLegend 107019; RRID: AB_2783049
TotalSeq-A0377 anti-mouse CD197
(CCR7) Antibody (clone 4B12)
BioLegend 120129
TotalSeq-A0378 anti-mouse CD223
(LAG-3) Antibody (clone C9B7W)
BioLegend 125229; RRID: AB_2783078
TotalSeq-A0379 anti-mouse CD62E (E-
selectin) Antibody (clone RME-1/CD62E)
BioLegend N/A
TotalSeq-A0381 anti-mouse
Panendothelial Cell Antigen Antibody (clone
MECA-32)






BioLegend 848009; RRID: AB_2783419
TotalSeq-A0416 anti-mouse CD300LG
(Nepmucin) Antibody (clone ZAQ5)
BioLegend 147105; RRID: AB_2783116
TotalSeq-A0422 anti-mouse CD172a
(SIRPa) Antibody (clone P84)
BioLegend 144033; RRID: AB_2800670
TotalSeq-A0424 anti-mouse CD14
Antibody (clone Sa14-2)
BioLegend 123333; RRID: AB_2800591
TotalSeq-A0426 anti-mouse CD192
(CCR2) Antibody (clone SA203G11)
BioLegend 150625; RRID: AB_2783122
TotalSeq-A0437 anti-mouse/human
CD207 Antibody (clone 4C7)
BioLegend N/A
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(Siglec-1) Antibody (clone N1/12)
BioLegend 142425; RRID: AB_2783106
TotalSeq-A0441 anti-mouse CD71
Antibody (clone 3D6.112)
BioLegend 113824; RRID: AB_2800574
TotalSeq-A0442 anti-mouse Notch 1
Antibody (HMN1-12)
BioLegend 130617; RRID: AB_2783085
TotalSeq-A0443 anti-mouse CD41
Antibody (clone MWReg30)
BioLegend 133937; RRID: AB_2800635
TotalSeq-A0448 anti-mouse CD204
(Msr1) Antibody (clone 1F8C33)
BioLegend 154703; RRID: AB_2783126
TotalSeq-A0449 anti-mouse CD326
(Ep-CAM) Antibody (clone G8.8)
BioLegend 118237; RRID: AB_2800586
TotalSeq-A0551 anti-mouse CD301a
(MGL1) Antibody (clone LOM-8.7)
BioLegend 145611; RRID: AB_2783114
TotalSeq-A0552 anti-mouse CD304
(Neuropilin-1) Antibody (clone 3E12)
BioLegend 145215; RRID: AB_2750383
TotalSeq-A0554 anti-mouse CD309
(VEGFR2, Flk-1) Antibody (clone 89B3A5)
BioLegend 121921; RRID: AB_2783066
TotalSeq-A0555 anti-mouse CD36
Antibody (clone HM36)
BioLegend 102621; RRID: AB_2800557
TotalSeq-A0556 anti-mouse CD370




BioLegend 102733; RRID: AB_2750556
TotalSeq-A0558 anti-mouse CD55 (DAF)
Antibody (clone RIKO-3)
BioLegend 131809; RRID: AB_2783086
TotalSeq-A0559 anti-mouse CD63
Antibody (clone NVG-2)
BioLegend 143915; RRID: AB_2783109
TotalSeq-A0560 anti-mouse CD68
Antibody (clone FA-11)
BioLegend 137031; RRID: AB_2783099
TotalSeq-A0561 anti-mouse CD79b (Igb)
Antibody (clone HM79-12)
BioLegend 132811; RRID: AB_2783087
TotalSeq-A0562 anti-mouse CD83
Antibody (clone Michel-19)
BioLegend 121519; RRID: AB_2783061
TotalSeq-A0563 anti-mouse CX3CR1
Antibody (clone SA011F11)
BioLegend 149041; RRID: AB_2783121
TotalSeq-A0564 anti-mouse Folate
Receptor b (FR-b) Antibody (clone 10/FR2)
BioLegend 153307; RRID: AB_2800690
TotalSeq-A0565 anti-mouse MERTK
(Mer) Antibody (clone 2B10C42)
BioLegend 151511
TotalSeq-A0566 anti-mouse CD301b
(MGL2) Antibody (clone URA-1)
BioLegend 146817; RRID: AB_2783115
TotalSeq-A0567 anti-mouse Tim-4
Antibody (clone RMT4-54)
BioLegend 130011; RRID: AB_2783084
TotalSeq-A0568 anti-mouse/rat XCR1
Antibody (clone ZET)
BioLegend 148227; RRID: AB_2783120
TotalSeq-A0570 anti-mouse/rat CD29
Antibody (clone HMb1-1)
BioLegend 102233; RRID: AB_2783042
TotalSeq-A0573 anti-mouse CD140a
Antibody (clone APA5)
BioLegend 135917; RRID: AB_2783094
TotalSeq-A0595 anti-mouse CD11a
Antibody (clone M17/4)
BioLegend 101125; RRID: AB_2783036
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TotalSeq-A0596 anti-mouse ESAM
Antibody (clone 1G8/ESAM)
BioLegend 136209; RRID: AB_2800642




Bodipy 493/503 Thermo Fisher D3922
Brefeldin BioLegend 420601
BUV805 - Streptavidin BD Horizon 564923
BV605 - Streptavidin BD Horizon 563260
Calcium chloride dihydrate Merck 1023821000




D(+)-Saccharose VWR International PROL27483.294
DAPI Invitrogen D1306; RIDD: AB_2629482
DMEM Invitrogen 41965-039
Dnase I Sigma-Aldrich 04 536 282 001
Donkey Serum Abcam ab7475
EDTA Westburg 51234
EGTA Sigma-Aldrich E3889
Eosin VWR International MERC 1.15935
FcBlock 2.4G2 Bioceros N/A
FCS Bodinco 5010
Fixable Viability due Live/Dead - eFluor506 eBioscience 65-0866-18
Fixable Viability due Live/Dead - eFluor780 eBioscience 65-0865-18
Fixation/Permeabilization Solution Kit BD Cytofix/Cytoperm 554714




GlutaMAX Thermo Fisher 35050-038
Gluteraldehyde 25% Sigma-Aldrich G5882
Goat Serum Sigma-Aldrich G9023
HCS LipidTOX Deep Red Invitrogen H34477
Hematoxylin VWR International MERC1.05174
HEPES Sigma-Aldrich H3375
Isopropanol Vel T0108
Methanol Merck Millipore 13680502
Monensin BioLegend 420701
Paraformaldehyde 10% EMS 15712
PE-Cy5 - Streptavidin BioLegend 405205
Phalloidin - Alexa Fluor 680 Invitrogen A22286
Phenol Red Sigma-Aldrich P3532
Poly-Lysine Sigma-Aldrich P8920
Potassium chloride Sigma-Aldrich P9541
Potassium Ferricyanide EMS 20150
ProLong Diamond Thermo Fisher P36970
Rat Serum Sigma-Aldrich R9759
(Continued on next page)
ll
OPEN ACCESS Article
e7 Immunity 53, 641–657.e1–e14, September 15, 2020
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
RPMI 1640 GIBCO 52400-025
Saponin Sigma-Aldrich 4521
Sodium bicarbonate Sigma-Aldrich 792519




Sodium phosphate dibasic dihydrate Sigma-Aldrich 71643
Tissue-Tek O.C.T Sakura Finetek 4583
Xylene Prolabo PROL28973.363
Critical Commercial Assays




PicroSirius Red Staining Kit Abcam ab150681
PrimeFlow RNA assay kit Thermo Fisher 88-18005-210
RNEasy Plus Micro Kit QIAGEN 74034
SensiFAST cDNA Synthesis Kit Bioline BIO-65054
SensiFAST SYBR No-ROX Kit Bioline BIO-98020
Spp1 Alexa Fluor 647 probes Type 1 for
PrimeFlow
Thermo Fisher PF-204
Triglyceride Colorimetric Assay Kit Cayman 10010303
Ultra Sensitive Mouse Insulin ELISA kit Crystal Chem Inc. 90080
Oligonucleotides
Actb - qPCR FWD IDT GCTTCTAGGCGGACTGTTACTGA
Actb - qPCR REV IDT GCCATGCCAATGTTGTCTCTTAT
Atf3 - qPCR FWD IDT GAGGATTTTGCTAACCTGACACC
Atf3 - qPCR REV IDT TTGACGGTAACTGACTCCAGC
Bmp10 - qPCR FWD IDT ACCAGACGTTGGCAAAAGTCAGGC
Bmp10 - qPCR REV IDT GATGATCCAGGAGTCCCACCCAAT
Bmp2 - qPCR FWD IDT TGCACCAAGATGAACACAGC
Bmp2 - qPCR REV IDT GTGCCACGATCCAGTCATTC
Bmp6 - qPCR FWD IDT AAGACCCGGTGGTGGCTCTA
Bmp6 - qPCR REV IDT CTGTGTGAGCTGCCCTTGCT
Calr - qPCR FWD IDT GAATACAAGGGCGAGTGGAA
Calr - qPCR REV IDT GGGGGAGTATTCAGGGTTGT
Cd36 - qPCR FWD IDT GGAGCCATCTTTGAGCCTTCA
Cd36 - qPCR REV IDT GAACCAAACTGAGGAATGGATCT
Col1a2 - qPCR FWD IDT TGAAGTGGGTCTTCCAGGTCTTTC
Col1a2 - qPCR REV IDT CACCCTTGTTACCGGATTCTCCTT
Cp - qPCR FWD IDT TCTACCAAGGAGTAGCCAGGA
Cp - qPCR REV IDT ATCTTCCCTCTCATCCGTGC
Csf1 - qPCR FWD IDT CGGGCATCATCCTAGTCTTGCTGACTGT
Csf1 - qPCR REV IDT ATAGTGGCAGTATGTGG
GGGGCATCCTC
Cxcl10 - qPCR FWD IDT GTCTGAGTGGGACTCAAGGGAT
Cxcl10 - qPCR REV IDT TCAACACGTGGGCAGGATAG
Cyp2e1 - qPCR FWD IDT GTTGCCTTGCTTGTCTGGAT
Cyp2e1 - qPCR REV IDT AGGAATTGGGAAAGGTCCTG
Dll4 - qPCR FWD IDT TTCCAGGCAACCTTCTCCGA
(Continued on next page)
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Dll4 - qPCR REV IDT ACTGCCGCTATTCTTGTCCC
Fabp4 - qPCR FWD IDT GATGAAATCACCGCAGACGACA
Fabp4 - qPCR REV IDT ATTGTGGTCGACTTTCCATCCC
Fga - qPCR FWD IDT TTCTGCTCTGATGATGACTGGAA
Fga - qPCR REV IDT GGCTTCGTCAATCAACCCTTT
Gdf2 - qPCR FWD IDT TGAGTCCCATCTCCATCCTC
Gdf2 - qPCR REV IDT ACCCACCAGACACAAGAAGG
Hspa5 - qPCR FWD IDT ACCCACCAAGAAGTCTCAGATCTT
Hspa5 - qPCR REV IDT CGTTCACCTTCATAGACCTTGATTG
Il1b - qPCR FWD IDT GCAACTGTTCCTGAACTCAACT
Il1b - qPCR REV IDT ATCTTTTGGGGTCCGTCAACT
Il34 - qPCR FWD IDT CTTTGGGAAACGAGAATTTGGAGA
Il34 - qPCR REV IDT GCAATCCTGTAGTTGATGGGGAAG
Il6 - qPCR FWD IDT TGATGGATGCTACCAAACTGG
Il6 - qPCR REV IDT TTCATGTACTCCAGGTAGCTATGG
Lcn2 - qPCR FWD IDT TGCCACTCCATCTTTCCTGTT
Lcn2 - qPCR REV IDT GGGAGTGCTGGCCAAATAAG
Mki67 - qPCR FWD IDT ATCATTGACCGCTCCTTTAGGT
Mki67 - qPCR REV IDT GCTCGCCTTGATGGTTCCT
Tgfb1 - qPCR FWD IDT CTCCCGTGGCTTCTAGTGC
Tgfb1 - qPCR REV IDT GCCTTAGTTTGGACAGGATCTG
Tnf - qPCR FWD IDT TCTTCTCATTCCTGCTTGTGG
Tnf - qPCR REV IDT GGTCTGGGCCATAGAACTGA
Tnfaip2 - qPCR FWD IDT AAACCAATGGTGATGGAAACTG
Tnfaip2 - qPCR REV IDT GTTGTCCCATTCGTCATTCC
Software and Algorithms
Adobe Illustrator Adobe www.adobe.com
Enrichr (Kuleshov et al., 2016) http://amp.pharm.mssm.edu/Enrichr/
FlowJo v10.6.1 FlowJo https://www.flowjo.com




GraphPad Prism 8 GraphPad https://www.graphpad.com/
Harmony (Korsunsky et al., 2019) https://www.github.com/
immunogenomics/harmony
Ilastik (Berg et al., 2019) https://www.ilastik.org/
ImageJ (Schneider et al., 2012) https://imagej.nih.gov/ij




WEB-based GEne SeT AnaLysis Toolkit (Liao et al., 2019) http://www.webgestalt.org/
Zen Black ZEISS Microscopy www.zeiss.com
Experimental Models
Mouse: B6(C)-Ccr2 tm1.1Cln/J The Jackson Laboratory JAX: 027619
Mouse: C57BL/6j SPF Janvier Labs N/A
Mouse: B6-Clec4fhDTR/YFP-CIPHE (Scott et al., 2016) N/A
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Charlotte
Scott (charlotte.scott@irc.vib-ugent.be).
Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
The datasets generated during this study have been deposited in the Gene Expression Omnibus public database under accession
number GEO: GSE156059.
Additional Resources
The scRNA-seq and CITE-seq datasets can be visualized, analyzed and downloaded at www.livercellatlas.org
EXPERIMENTAL MODEL AND SUBJECT DETAILS
In Vivo Animal Studies
The followingmicewere used in this study; C57BL/6J (Janvier), Ccr2GFP/+ (Satpathy et al., 2013) andClec4f-DTR (Scott et al., 2016).
All micewere used on aC57BL/6 background and onlymalemicewere used for diet experiments while amix ofmale and femalemice
were used for all experiments performed with normal chow diet. Mice were put on the diets from 5 weeks of age and sacrificed at
indicated time points. All other mice were used between 6 and 12 weeks of age. All mice were bred and/or maintained at the VIB
(Ghent University) under specific pathogen free conditions. All animals were randomly allocated to experimental groups. All exper-
iments were performed in accordance with the ethical committee of the Faculty of Science, UGent and VIB.
METHOD DETAILS
Diet induced MAFLD
To induce MAFLD and NASH, mice were fed a western diet (WD) high in fat, sugar and cholesterol as described previously (Ganz
et al., 2015). This consisted of 58% fat, 1% cholesterol (Research Diets; D09061703i) and drinking water was supplemented with
23.1g/L fructose (MPBio) and 18.9g/L sucrose (VWR). Control mice were fed a standard diet with 11kcal% fat with corn starch
(D12328i; Research Diets).
Intraperitoneal Glucose Tolerance Test
Following overnight fastening, mice were administered 2g/kg glucose via intraperitoneal injection. Blood glucose concentrations
were measured 0, 15, 30, 60, 120 and 180 min later.
Insulin ELISA
Following overnight fasting, blood was collected from the tail, serum was collected and fasting insulin were measured on undiluted
serum according to the manufacturer’s instructions using the Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem)
Colorimetric assays
After sacrifice, mice were bled by cardiac puncture and serumwas collected. Serum cholesterol & cholesteryl esters were measured
according to the manufacturer’s instructions using the Cholesterol & Cholesteryl Ester Quantitation Kit (Abnova). Serum triglycerides
were measured according to the manufacturer’s instructions using the Triglyceride Colorimetric Assay Kit (Cayman).
Histological analysis
Livers were removed rapidly, a piece taken and fixed immediately in fresh 4%paraformaldehyde at RT for 24 h. Fixed livers were then
dehydrated and embedded in paraffin, after which 5 mm cross sections were obtained using a Microm HM360. Sections were then
deparaffinized, rehydrated and stained with hematoxylin and eosin using standard protocols. Sections were also stained for Picro-
Sirius Red according to the manufacturer’s instructions using the Picro Sirius Red Stain kit (Abcam). Sections were imaged using a
Zeiss AxioScan.Z1.
Isolation of Liver Cells
Liver cells were isolated by liver perfusion and digestion as described previously (Bonnardel et al., 2019). Briefly, after retrograde
cannulation, livers were perfused for 1-2mins with an EGTA-containing solution, followed by a 5min (6ml/min) perfusion with
0.2mg/mL collagenase A. Livers were then removed, minced and incubated for 20mins with 0.4mg/mL collagenase A and 10U/
mLDNase at 37C. All subsequent procedures were performed at 4C. Samples were filtered over a 100 mmmesh filter and red blood
cells were lysed. Samples were again filtered over a 40 mm mesh filter. After two centrifugation steps of 1 min at 50 g to isolateImmunity 53, 641–657.e1–e14, September 15, 2020 e10
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staining for flow cytometry.
Flow Cytometry and Cell Sorting
0.5-5x106 cells were pre-incubated with 2.4G2 antibody (Bioceros) to block Fc receptors and stained with appropriate antibodies at
4C in the dark for 30-45min. Cell viability was assessed using Fixable Viability dyes (eFluor780 or eFluor506; Thermo Fisher) and cell
suspensions were analyzedwith a BD FACSymphony or purified using a BD FACSAria II or III and FlowJo software (BD). Bodipy stain-
ing (Thermo Fisher) was performed after surface antibody staining for 15 min at room temperature. The full list of antibodies used can
be found in the Key Resource Table. The Primeflow assay (Thermo Fisher) for Spp1 expression was performed in 96-well U-bottom
plates according to the manufacturer’s instructions. Ki67 and Tbet staining was performed by fixing and permeabilizing extracellu-
larly stained cells according to the manufacturer’s instructions using the FoxP3 Transcription factor staining buffer Kit (eBioscience).
Lipidtox staining was performed after fixing and permeabilizing extracellularly stained cells according to the manufacturer’s instruc-
tions using the Fixation/Permeabilization Solution Kit (BD Cytofix/Cytoperm). To measure intracellular cytokines, 0.5-5x106 cells
were incubated for 3.5 h at 37C in DMEM with 10%FCS, 1% glutamax, 0.1% b-mercaptoethanol, 0.5% gentamicin with 1X mon-
ensin and 1X brefeldin A (Biolegend). After incubation, cells were stained extracellularly as above. Intracellular cytokine staining was
performed by fixing and permeabilizing extracellularly stained cells according to the manufacturer’s instructions using the Fixation/
Permeabilization Solution Kit (BD Cytofix/Cytoperm).
Confocal microscopy
Confocal staining was performed as described previously (Bonnardel et al., 2019). Immediately after sacrificing mice with CO2, infe-
rior vena cava were cannulated and livers were perfused (4 mL/min) with Antigenfix (Diapath) for 5 min at room temperature. After
excision, 2-3 mm slices of livers were fixed further by immersion in Antigenfix for 1 h at 4C, washed in PBS, infused overnight in
34% sucrose and frozen in Tissue-Tek OCT compound (Sakura Finetek). 20 mm-thick slices cut on a cryostat (Microm HM 560,
Thermo Scientific) were rehydrated in PBS for 5 min, permeabilized with 0.5% saponin and non-specific binding sites were blocked
for 30min with 2%bovine serum albumin, 1% fetal calf serum and 1%donkey or goat serum for 30min. Tissue sections were labeled
overnight at 4Cwith primary antibodies followed by incubation for 1 h at room temperature with secondary antibodies. When two rat
antibodies were used on the same section, the directly conjugated rat antibody was incubated for 1 h after staining with the uncon-
jugated and anti-rat secondary and after an additional blocking step with 1% rat serum for 30 min. Slides were mounted in ProLong
Diamond, imaged with a Zeiss LSM780 confocal microscope (Carl Zeiss, Oberkochen, Germany) with spectral detector and using
spectral unmixing and analyzed using ImageJ and QuPath software.
Generation of BM chimeras
Bonemarrow chimeraswere generated as described previously (Scott et al., 2016). Briefly, 5 week oldmale C57BL/6Jwild-typemice
(CD45.2) on normal chow were anaesthetized by intraperitoneal administration of Ketamine (150 mg/kg) and Xylazine (10 mg/kg).
Mice were lethally irradiated with 8 Gy, with the livers being protected with a 3-cm-thick lead cover. Once recovered from the anes-
thesia, micewere reconstituted by intravenous administration of 5-103 106 BMcells fromCD45.1/CD45.2wild-typemice.Micewere
placed on either the SD or WD immediately after reconstitution. Chimerism was assessed 18 or 24 weeks after irradiation by flow
cytometry.
CSF1Fc administration
Mice received the SD or WD for 24 weeks, before being injected subcutaneously with 1 mg/kg CSF1Fc or PBS for 4 days. Mice were
sacrificed on day 6 and the % and number of KCs was assessed by flow cytometry.
DT administration
Clec4f-DTRmice orWT littermate controls were injected intraperitoneally with 500ng DT.Mice were sacrificed on 3 or 6 days after DT
administration.
RNA Sequencing, CITE-seq and qPCR
Sorting and RNA Isolation
40000-160000 live CD45+ cells or CD45- cells from livers of a C57BL/6mouse fed the SDorWD for 12, 24 and 36weekswere purified,
centrifuged at 400 g for 5 min and stained with 2.4G2 antibody to block Fc receptors and CITE-seq antibodies for 20mins at 4C,
before being washed in excess PBS with 2% FCS and 2mM EDTA. Cells were then resuspended in PBS with 0.04% BSA at
1000 cells/mL. Cell suspensions (target recovery of 8000-10000 cells) were loaded on a GemCode Single-Cell Instrument (10x Ge-
nomics, Pleasanton, CA, USA) to generate single-cell Gel Bead-in-Emulsions (GEMs). ScRNA-Seq libraries were prepared using
GemCode Single-Cell 3ʹGel Bead and Library Kit (10x Genomics, V3 technology) according to the manufacturer’s instructions.
Briefly, GEM-RT was performed in a 96-Deep Well Reaction Module: 55C for 45min, 85C for 5 min; end at 4C. After RT, GEMs
were broken down and the cDNA was cleaned up with DynaBeads MyOne Silane Beads (Thermo Fisher Scientific, 37002D) and
SPRIselect Reagent Kit (SPRI; Beckman Coulter; B23318). cDNA was amplified with 96-Deep Well Reaction Module: 98C for
3 min; cycled 12 times: 98C for 15 s, 67C for 20 s, and 72C for 1 min; 72C for 1 min; end at 4C. Amplified cDNA product wase11 Immunity 53, 641–657.e1–e14, September 15, 2020
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reagents in the GemCode Single-Cell 3ʹ Library Kit with the following intermediates: (1) end repair; (2) A-tailing; (3) adaptor ligation;
(4) post-ligation SPRIselect cleanup and (5) sample index PCR. Pre-fragmentation and post-sample index PCR samples were
analyzed using the Agilent 2100 Bioanalyzer.
qPCR
RNA was extracted from 25000 sorted macrophages (CLEC4F+ TIM4+, CLEC4F+ TIM4- or CLEC4F- TIM4-) or from 5000-25000 He-
patocytes, LSECs, HSCs or cholangiocytes from livers of C57BL/6 mice fed the SD or WD for 12, 24 and 36 weeks using a RNeasy
Plus micro kit (QIAGEN). Sensifast cDNA synthesis kit (Bioline) was used to transcribe total RNA to cDNA. Real-time RT-PCR using
SensiFast SYBR No-Rox kit (Bioline) was performed to determine gene expression, therefore a PCR amplification and detection in-
strument LightCycler 480 (Roche) was used. Gene expression was normalized to b-actin gene expression.
Bulk RNA Sequencing Analysis
Libraries were constructed using the Illumina TruSeq RNA Preparation Kit. RNA sequencing was performed at the VIB Nucleomics
Core using Illumina NextSeq500 with these parameters: High Output v2.5, 75 bp, Single Reads (76-8-8-0), 1.4 pM + 1.73% PhiX. All
samples passed quality control based on the results of FastQC (v0.11.9). Reads were mapped to the mouse reference genome
(mm10) via HiSat2 (v2.2.0) with max-intronlen set to 1000000. The aligned reads were counted via FeatureCounts (v2.0.0). The R
package limma (v3.42.2) was used to normalize the data and to perform differential expression analysis. Genes that didn’t have a
count per million (cpm) value > 1 in at least 5 samples were removed. As such, we continued with 13421 genes. Benjamini-Hochberg
was used to adjust the p values for multiple testing. The DE genes were defined based on a log2-ratio > 1 or < 1 and adj.P value <
0.05. For the heatmap we first transformed the normalized expression table as ‘log2(2^expTable + 1)’ and subsequently scaled the
values per gene by calculating the mean expression per gene and then subtracting that mean value of each expression value. The R
package triwise (v0.99.5) was used to create the triwise plots.
scRNA-Sequencing Analysis
Sequencing libraries were loaded on an Illumina HiSeqwith sequencing settings recommended by 10XGenomics (26/8/0/98 – 2.1pM
loading concentration, ADT and cDNA libraries were pooled in a 25:75 ratio). Sequencing was performed at the VIB Nucleomics Core
(VIB, Leuven). The demultiplexing of the raw data was performed using CellRanger software (10x – version 3.1.0; cellranger mkfastq
which wraps Illumina’s bcl2fastq). The reads obtained from the demultiplexing were used as the input for ‘cellranger count’ (Cell-
Ranger software), which aligns the reads to the mouse reference genome (mm10) using STAR and collapses to unique molecular
identifier (UMI) counts. The result is a large digital expression matrix with cell barcodes as rows and gene identities as columns.
The aggregation of the samples was performed using ‘cellranger aggr’ (CellRanger software).
Preprocessing Data
Preprocessing of the data was done by the scater R package (v1.12.2) according to workflow proposed by theMarioni lab (Lun et al.,
2016). Outlier cells were identified based on 3 metrics (library size, number of expressed genes and mitochondrial proportion) and
cells were first tagged as outliers when they were x median absolute deviation (MADs) higher or lower than the median value of
each metric. For library size 4 MADs was used, for the number of expressed genes 4 MADs for used and for the mitochondrial pro-
portion 5 MADs was used. For the patient data were respectively 3 MADs, 3 MADs and 5 MADs used. As second filtering, a principal
component analysis plot was generated using the runPCA function of the scater R package (default parameters). Outlier cells in this
principal component analysis plot were identified using the R packagemvoutlier. For the CD45- cells, due to inclusion of hepatocytes
an additional cleanup was necessary to remove ambient mRNA signals. Samples were corrected for ambient RNA using the R pack-
age FastCAR (v0.1.0). We defined an empty droplet as a cell barcode with at least 10 UMIs and less than a certain cut off. To define
this cut off we first made a plot showing on the y axis how many UMIs are present in a barcode and on the x-as the number of barc-
odes (same plot as in the CellRanger web_summary output). Bymaking this plot, a clear ‘drop’ in UMI counts becomes visible andwe
put our cut off just before this ‘drop’. This cut off is always lower than theminimal UMI count from the ‘filtered’ CellRanger output. The
corrected counts were merged together using the R package Harmony (v1.0). For all samples, after these initial analysis steps, addi-
tional low quality (low UMI counts, > 8% of mitochondrial genes), contaminating (potential doublets) and actively proliferating cells
were also removed from the analysis. Low-abundance genes were removed by removing all genes that weren’t expressed (count > 0)
in at least 3 cells. The counts were normalized and log2 transformed via the NormalizeData function of the Seurat R package (v3.1.1)
using default parameters. Detecting highly variable genes, finding clusters and creating UMAP plots was done using the Seurat pipe-
line. For the clustering, the first 20 principal components were used and 0.6 was used as the resolution parameter. The monocyte-
macrophage UMAPwas generated starting from the counts and using specific cells from the full UMAP (based onMafb, Ly6c2, Fcgr1
and Adgre1 expression, 21156 cells). Then the same Seurat pipeline was followed as described above. The first 20 PCs were used
and 0.8 was the resolution parameter. Differential gene expressionwas assessed using the findMarker function of the Seurat pipeline.
For the CITE-Seq data, we first checked in how many cells each antibody was expressed. The lowest expressed antibody was
expressed in only 1 cell and was hence excluded from further analysis, while the second lowest antibody was expressed in 41%
of the cells. The expression data were processed using the Seurat workflow, with CLR normalization and scaling of the data per-
formed using the default parameters. Marker Enrichment Modeling (Diggins et al., 2017) was performed on the CITE-Seq data using
theMEMRpackage (v2.0.0). TheMEMheatmapwas generated using pheatmap (v1.0.12). For each antibody we checked per cluster
if the MEM values were similar to those of the isotype control antibodies. When MEM values of an antibody are ± 0.5 compared with
the MEM values of the isotype across all clusters, the antibody was considered to not give a real signal above background and wasImmunity 53, 641–657.e1–e14, September 15, 2020 e12
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collating all cells with a count > 0 and calculating the 98% quantile cut-off of counts, with all the cells above this value being colored
in red.
Metabolomic profiling of Macrophages
ResKCs (10x104 – 25x104) were sorted in DMEM supplemented with 10% FCS (Bodinco) using a BD FACSARIA II and ARIA III. Cells
were then incubated for 30 min at 37C, before being pelleted at 9C and washed in 1ml ice cold NaCl (0.9%). Cells were then pel-
leted at9C and snap frozen in liquid nitrogen. Samples were than extracted in 100uL of 30:50:20 acetonitrile:methanol:milli-Q H2O
pre-cooled at 20C, dried using speed vac and resuspended in 20uL of 30:50:20 acetonitrile:methanol:milli-Q H2O for metabolites
that are identified in negative ionization mode (polar), or in H2O for metabolites that are identified in positive ionization mode (non-
polar). Metabolite quantification was carried out using Agilent 1290 Infinity II UHPLC in linewith a Bruker impact II QTOF-MSoperated
in full scan (MS1) mode. LC separation was performed on aWaters CSH-C18 column (1003 2.1 mm, 1.7 mmparticles) using a binary
solvent gradient of 100%buffer A (0.1% formic acid inwater) to 97%buffer B (50:50methanol:acetonitrile). Flow rate was 400 mL/min,
autosampler temperature was 4C, and injection volume was 3 mL. Data processing was performed using TASQTM Software (Target
Analysis for Screening and Quantification) (Bruker Daltonics Inc.).
Generation of M0, M1 and M2 in vitro macrophages
Bone marrow cells were isolated from tibias and femurs of WT mice and grown in complete medium (RPMI-1640 medium containing
10 mM glucose, 2 mM L-glutamine, 100 U ml–1 penicillin-streptomycin and 10% FCS) with 20 ng ml–1 murine macrophage colony-
stimulating factor 1 (CSF-1; Peprotech) for 7 days, and supplemented with CSF-1 on days 3 and 5. On day 7 macrophages were
harvested and then maintained in 20 ng ml–1 CSF-1 for subsequent experiments in which they were either maintained in medium
alone (M0), or stimulated with 50 ng ml–1 IFN-g (R&D systems) and 20 ng ml-1 LPS (M1), or 20 ng ml–1 IL-4 (M2) (Peprotech) for 18 h.
Lipidomic profiling of Macrophages
The protocol for lipid extraction was adapted fromMatyash et al. (Matyash et al., 2008). Frozen cell pellets (60000-150000 cells) were
resuspended in ice cold PBS and transferred to glass tubes before the addition of methanol and methyl tert-butyl ether. The tubes
were then shaken for 1 h at 4C. Water was added to separate the phases before centrifugation at 1,000 x g for 10 min. The upper
organic phase was collected and dried in a Genevac EZ2 speed vac. Samples were resuspended in 2:1:1 isopropanol:acetonitrile:-
milli-Q H2O prior to analysis. LC-MSwas carried out using an Agilent Zorbax Eclipse Plus C18 column using an Agilent 1290 Infinity II
UHPLC inline with an Agilent 6495 Triple Quad QQQ-MS. Lipids were identified by fragmentation and retention time, and were quan-
tified using Agilent Mass Hunter software.
HCS LipidTOX Deep Red staining for microscopy
25000 ResKCs were sorted into DMEM supplemented with 10% FCS (Bodinco) using an ARIA II and ARIA III (BD Biosciences). Cells
were incubated on coverslips pre-coated with poly-lysine for 30 min at 37C. Cells were washed and then fixed using Antigenfix (Di-
apath). Cells were washed and stained with DAPI (Invitrogen) and LipidTOX Deep Red staining (Invitrogen) for 1 h at room temper-
ature. Slides were mounted in ProLong Diamond, imaged with a Zeiss LSM780 confocal microscope (Carl Zeiss, Oberkochen, Ger-
many) and analyzed using ImageJ software.
FIB-SEM
100000 CLEC4F+ KCs were sorted into DMEM supplemented with 10% FCS (Bodinco) using a BD FACSARIA II and ARIA III. Cells
were resuspended in DMEM+10%FCS at room temperature andwere incubated for 2 h at 37C to adhere onto coverslips. Following
that, samples were incubated in freshly prepared fixative (2% paraformaldehyde (PFA, Applichem), 2.5% glutaraldehyde (GA, EMS)
in 0.1M sodium cacodylate (Sigma-Aldrich) buffer, pH7.4) at RT for 30 min. Fixative was removed by washing in 0.1M cacodylate
buffer and samples were incubated in 1% osmium (OsO4, EMS), 1.5% potassium ferrocyanide (Sigma-Aldrich) in 0.1M cacodylate
buffer for 40min at RT. After washing in ddH2O, samples were incubated overnight at 4C in 1:3 UAR in H2O (Uranyl Acetate Replace-
ment, EMS). The next day, UAR was removed by washing in ddH2O. After final washing steps the samples were dehydrated using
solutions of increasing EtOH concentration (30%, 50%, 70%, 90%, 2x 100%) for 3 min each. Subsequent infiltration with resin
(Spurr’s, EMS) was done by first incubating in 50% resin in ethanol for 2 h, followed by at least 3 changes of fresh 100% resin
(including 1 overnight incubation). Next, samples were embedded in fresh resin and cured in the oven at 65C for 72 h.
For FIB-SEM imaging, embedded cells were mounted on aluminum SEM stubs (diameter 12 mm) using conductive epoxy (Circuit
Works) and samples were coated with 20nm of Platinum (Quorum Q150T ES). FIB-SEM imaging was performed using a Zeiss
Crossbeam 540 system with Atlas5 software. The Focused Ion Beam (FIB) was set to remove 5nm sections by propelling gallium
ions at the surface. Imaging was performed at 1.5kV and 1nA using an ESB (back-scattered electron) detector.
Lipid droplet analysis
The FIB-SEM data was segmented using deep convolutional neural networks, specifically U-Net (Ronneberger et al., 2015). In total,
2292 patches of size 256x256 were selected across 8 samples. The pixels in these patches that correspond to lipid droplets were
labeled by an expert. The obtained labeled dataset was split in 66/34% train/test data. For training the network, we employede13 Immunity 53, 641–657.e1–e14, September 15, 2020
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smaller as in (Ronneberger et al., 2015)) and standard data augmentations (small scaling, rotations, flips, random deformations and
noise perturbations). A threshold is then applied to the final probability maps to obtain a segmentation of the droplets. This segmen-
tation was further cleaned by removing noise components (objects smaller than 3x3x3 = 27 voxels) and applying a morphological
opening with a spherical structure element (radius of 2 voxels). This final segmentation allowed us to extract the total volume of
the droplets. The neural network was implemented in PyTorch and post-processing was performed usingMATLAB. The code is pub-
licly available on www.github.com/jorisroels/lipid-droplets.
Quantification of Microscopy
To detect the Macrophages, a custom groovy script (used with the eleventh milestone release on the path to QuPath v0.2.0) (Bank-
head et al., 2017) has been written using the F4/80 marker, and then cells have been classified based on their CLEC4F, TIM4 and F4/
80 expression. The script splits the image into tiles, extracts the F4/80 channel image, applies a median filter to remove the noise,
applies a threshold to keep only the positive signal object and uses the Analyze Particles from ImageJ to filter the smallest particle by
area. The ROIs (Region of Interest) are sent to Qupath as annotation, the adjacent annotations due to the tiling are merged back and
holes within the annotations are filled and converted to cell detections. Script is available upon request.
Feature extraction was performed using QuPath and detected cells classified using QuPath based on their CLEC4F, TIM4 and F4/
80 expression. Identification of Desminhi areas was performed using QuPath: based on pixel intensity from the Desmin channel, a
pixel classifier was trained, the high/low Desmin Areas detected and the number of each cell type was then counted in Desminhi
and Desminlo areas. Large vessels were identified manually based on expression of Desmin and CD31 and these regions were
excluded from the analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
In all experiments, data are presented asmean ± SEMand/or individual data points are presented unless stated otherwise. Statistical
tests were selected based on appropriate assumptions with respect to data distribution and variance characteristics. Student’s t test
(two-tailed) was used for the statistical analysis of differences between two groups. One-way ANOVAwith Bonferroni’s multiple com-
parisons test was used for the statistical analysis of differences between more than two groups. Details of the precise test used for
each analysis can be found in the figure legends. Statistical significance was defined as p < 0.05. Sample sizes were chosen accord-
ing to standard guidelines. Number of animals is indicated as ‘‘n’’. The investigators were not blinded to the mouse group allocation.Immunity 53, 641–657.e1–e14, September 15, 2020 e14
